References
- World Health Organization. Ebola virus disease; 2019. [accessed 2019 Dec 18]. https://www.who.int/en/news-room/fact-sheets/detail/ebola-virus-disease
- Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, Belaganahalli MN, Wells HL, Dhanota JK, Liang E, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol. 2018;3:1084–15. doi:https://doi.org/10.1038/s41564-018-0227-2.
- Forbes KM, Webala PW, Jaaskelainen AJ, Abdurahman S, Ogola J, Masika MM, Kivisto I, Alburkat H, Plyusnin I, Levanov L, et al. Bombali virus in mops condylurus Bat, Kenya. Emerg Infect Dis. 2019;25. doi:https://doi.org/10.3201/eid2505.181666.
- Centers for Disease Control and Prevention. Ebola virus outbreaks by species and size, since 1976; 2019. [accessed 2019 Dec 20]. https://www.cdc.gov/vhf/ebola/history/distribution-map.html
- Parra JM, Salmeron OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. N Engl J Med. 2014;371:2439–40. doi:https://doi.org/10.1056/NEJMc1412662.
- Liddell AM, Davey RT Jr., Mehta AK, Varkey JB, Kraft CS, Tseggay GK, Badidi O, Faust AC, Brown KV, Suffredini AF, et al. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med. 2015;163:81–90. doi:https://doi.org/10.7326/M15-0530.
- Centers for Disease Control and Prevention (CDC). History and outbreaks of Ebola virus disease; 2018. [accessed 2019 Dec 20]. https://www.cdc.gov/vhf/ebola/history/distribution-map.html
- Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 1995;345:1271–74. doi:https://doi.org/10.1016/S0140-6736(95)90925-7.
- Burk R, Bollinger L, Johnson JC, Wada J, Radoshitzky SR, Palacios G, Bavari S, Jahrling PB, Kuhn JH. Neglected filoviruses. FEMS Microbiol Rev. 2016;40:494–519. doi:https://doi.org/10.1093/femsre/fuw010.
- Cross RW, Mire CE, Feldmann H, Geisbert TW. Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discovery. 2018;17:413–34. doi:https://doi.org/10.1038/nrd.2017.251.
- Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019;17:593–606. doi:https://doi.org/10.1038/s41579-019-0233-2.
- Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53. doi:https://doi.org/10.1038/nature13777.
- Qiu X, Audet J, Lv M, He S, Wong G, Wei H, Luo L, Fernando L, Kroeker A, Fausther Bovendo H, et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med. 2016;8:329ra33. doi:https://doi.org/10.1126/scitranslmed.aad9875.
- Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351:1339–42. doi:https://doi.org/10.1126/science.aad5224.
- Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, CD M, Turner HL, Fairhurst J, Torres M, Rafique A, et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J Infect Dis. 2018;218:S612–S26. doi:https://doi.org/10.1093/infdis/jiy285.
- Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381–85. doi:https://doi.org/10.1038/nature17180.
- New antibodies best ZMapp in Ebola trial. Nat Biotechnol. 2019;37:1105. doi:https://doi.org/10.1038/s41587-019-0284-y.
- Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2016;90:279–91. doi:https://doi.org/10.1128/JVI.02172-15.
- Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016;351:1078–83. doi:https://doi.org/10.1126/science.aad5788.
- Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell. 2017;169:891–904 e15. doi:https://doi.org/10.1016/j.cell.2017.04.038.
- Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, et al. Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the Ebolavirus glycoprotein. Immunity. 2018;49:363–74 e10. doi:https://doi.org/10.1016/j.immuni.2018.06.018.
- Fischer WA, Brown J, Wohl DA, Loftis AJ, Tozay S, Reeves E, Pewu K, Gorvego G, Quellie S, Cunningham CK, et al. Ebola virus ribonucleic acid detection in semen more than two years after resolution of acute ebola virus infection. Open Forum Infect Dis. 2017;4:ofx155. doi:https://doi.org/10.1093/ofid/ofx155.
- Zhu F-C, Hou L-H, Li J-X, Wu S-P, Liu P, Zhang G-R, Hu Y-M, Meng F-Y, Xu -J-J, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. 2015; 385:2272–79. doi:https://doi.org/10.1016/s0140-6736(15)60553-0
- Zhu F-C, Wurie AH, Hou L-H, Liang Q, Li Y-H, Russell JBW, Wu S-P, Li J-X, Hu Y-M, Guo Q, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389:621–28. doi:https://doi.org/10.1016/s0140-6736(16)32617-4.
- Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A. 1997;94:14764–69. doi:https://doi.org/10.1073/pnas.94.26.14764.
- Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454:177–82. doi:https://doi.org/10.1038/nature07082.
- Ng M, Ndungo E, Jangra RK, Cai Y, Postnikova E, Radoshitzky SR, Dye JM, Ramirez de Arellano E, Negredo A, Palacios G, et al. Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1. Virology. 2014;468-470:637–46. doi:https://doi.org/10.1016/j.virol.2014.08.019.
- Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, Gao GF. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell. 2016;164:258–68. doi:https://doi.org/10.1016/j.cell.2015.12.044.
- Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, et al. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep. 2016;6:25856. doi:https://doi.org/10.1038/srep25856.
- Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ. Mechanism of binding to ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol. 2015;89:10982–92. doi:https://doi.org/10.1128/JVI.01490-15.
- Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, Parks R, Whitesides J, Marshall DJ, Hwang KK, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods. 2009;158:171–79. doi:https://doi.org/10.1016/j.jviromet.2009.02.014.
- Liu W, Ren J, Zhang J, Song X, Liu S, Chi X, Chen Y, Wen Z, Li J, Chen W. Identification and characterization of a neutralizing monoclonal antibody that provides complete protection against Yersinia pestis. PLoS One. 2017;12:e0177012. doi:https://doi.org/10.1371/journal.pone.0177012.
- Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell. 2015;160:893–903. doi:https://doi.org/10.1016/j.cell.2015.01.031.
- Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. Embo J. 2012;31:1947–60. doi:https://doi.org/10.1038/emboj.2012.53.
- Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega M-A, Zhu W, et al. Antibodies from a human survivor define sites of vulnerability for broad protection against Ebolaviruses. Cell. 2017;169:878–90.e15. doi:https://doi.org/10.1016/j.cell.2017.04.037.
- Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O’Toole T, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. Jama. 2002;287:2391–405. doi:https://doi.org/10.1001/jama.287.18.2391.
- Yang XL, Tan CW, Anderson DE, Jiang RD, Li B, Zhang W, Zhu Y, Lim XF, Zhou P, Liu XL, et al. Characterization of a filovirus (Mengla virus) from Rousettus bats in China. Nat Microbiol. 2019;4:390–95. doi:https://doi.org/10.1038/s41564-018-0328-y.
- U.S. Food and Drug Administration. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response; 2019. [accessed 2019 Dec 22]. https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health?utm_campaign=121919_PR_First%20FDA-approved%20vaccine%20for%20the%20prevention%20of%20Ebola%20virus%20disease&utm_medium=email&utm_source=Eloqua
- Ehrhardt SA, Zehner M, Krahling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, et al. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nat Med. 2019;25:1589–600. doi:https://doi.org/10.1038/s41591-019-0602-4.
- Rijal P, Elias SC, Machado SR, Xiao J, Schimanski L, O’Dowd V, Baker T, Barry E, Mendelsohn SC, Cherry CJ, et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell Rep. 2019;27:172–86 e7. doi:https://doi.org/10.1016/j.celrep.2019.03.020.
- Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, et al. Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection. Cell. 2018;174:938–52.e13. doi:https://doi.org/10.1016/j.cell.2018.07.033.
- Saphire EO, Aman MJ. Feverish quest for ebola immunotherapy: straight or cocktail? Trends Microbiol. 2016;24:684–86. doi:https://doi.org/10.1016/j.tim.2016.05.008.
- de La Vega MA, Wong G, Kobinger GP, Qiu X. The multiple roles of sGP in Ebola pathogenesis. Viral Immunol. 2015;28:3–9. doi:https://doi.org/10.1089/vim.2014.0068.
- Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE Jr., et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell. 2015;160:904–12. doi:https://doi.org/10.1016/j.cell.2015.01.041.
- Wang Y, Sundling C, Wilson R, O’Dell S, Chen Y, Dai K, Phad GE, Zhu J, Xiao Y, Mascola JR, et al. High-resolution longitudinal study of HIV-1 Env vaccine-elicited B cell responses to the virus primary receptor binding site reveals affinity maturation and clonal persistence. J Immunol. 2016;196:3729–43. doi:https://doi.org/10.4049/jimmunol.1502543.
- Sholukh AM, Mukhtar MM, Humbert M, Essono SS, Watkins JD, Vyas HK, Shanmuganathan V, Hemashettar G, Kahn M, Hu SL, et al. Isolation of monoclonal antibodies with predetermined conformational epitope specificity. PLoS One. 2012;7:e38943. doi:https://doi.org/10.1371/journal.pone.0038943.
- Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4:372–84. doi:https://doi.org/10.1038/nprot.2009.3.
- Chi X, Li J, Liu W, Wang X, Yin K, Liu J, Zai X, Li L, Song X, Zhang J, et al. Generation and characterization of human monoclonal antibodies targeting anthrax protective antigen following vaccination with a recombinant protective antigen vaccine. Clin Vaccine Immunol. 2015;22:553–60. doi:https://doi.org/10.1128/CVI.00792-14.
- Zhao Y, Gutshall L, Jiang H, Baker A, Beil E, Obmolova G, Carton J, Taudte S, Amegadzie B. Two routes for production and purification of Fab fragments in biopharmaceutical discovery research: papain digestion of mAb and transient expression in mammalian cells. Protein Expr Purif. 2009;67:182–89. doi:https://doi.org/10.1016/j.pep.2009.04.012.